Placeholder

China’s Pharma Star Shines Bright

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

With a population of 1.3 billion people, China is both the world’s most populous nation and the fastest-growing major economy.
China has long had a reputation for low-cost labor and cheap exports. But according to a report from KPMG, China’s Pharmaceutical Industry Poised for the Giant Leap, China is turning away from this model and is focusing on socioeconomic development and resource sustainability.
The Chinese government laid out development goals in 2010 called the “125” plan, the country’s 12 Five-Year Plan (2011-2015), which places emphasis on greater welfare measures, public service, and more equitable distribution of wealth. Top priorities for the government are healthcare reform to ensure all citizens have basic medical coverage, modernizing the health infrastructure, improving…

Sidebars:
China: The Top 20 Conditions
Regulatory Opportunities and Challenges

Experts
Francis Cao
. Senior Director of Government Affairs and Public ­Relations, Beigene, a Chinese biotechnology company based in Beijing that is focused on discovering and ­developing innovative oncology drugs to ­address unmet medical needs in cancers that are prevalent in China and the Asia-Pacific ­region. For more information, visit beigene.com.
Marc Finn. Senior Director, ­Business Development, Suzhou Pharma Services, a contract ­development and manufacturing organization with its primary manufacturing site located in Suzhou, China. For more ­information, visit suzhoupharma.com.
Terry Hisey. Vice Chairman and U.S. Life Sciences Leader, Deloitte, which provides audit, consulting, ­financial advisory, risk ­management, and tax services. For more ­information, visit deloitte.com.
Clancey Houston. Managing Director, Chandler Chicco ­Companies’ China operations, which operates as inVentiv Health Communications company, is a multi-
disciplinary integrated communications group. For more information, visit chandlerchiccocompanies.com or inventivhealth.com.
Simon Li. General Manager, Kantar Health China, a global, evidence-based decision support partner to pharmaceutical, biotech, device, and diagnostic companies. For more ­information, visit kantarhealth.com.
Ling Zhen. General Manager, ­Quintiles, China, a fully integrated biopharma services ­company ­offering clinical, ­commercial, ­consulting, and capital solutions worldwide. For more information, visit quintiles.com.

FEEDBACK